Uterus Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Diagnose benign or malignant diseases affecting female reproductive organs

₹899₹1,700

47% OFF

Uterus Biopsy -XL: Comprehensive Medical Test Information Guide

Why is it done?
- Test Description: A uterus biopsy is a procedure in which a small sample of endometrial tissue (uterine lining) is collected for microscopic examination and pathological analysis to diagnose various uterine conditions.
- Primary Indications: Investigation of abnormal uterine bleeding (AUB), postmenopausal bleeding, suspected endometrial hyperplasia, evaluation of infertility, suspected endometrial malignancy, recurrent miscarriages, abnormal uterine pathology on imaging, and chronic endometritis.
- Timing and Circumstances: Performed during the luteal phase of the menstrual cycle when possible (days 21-23), in non-pregnant women, typically in outpatient gynecology settings, or when persistent uterine symptoms warrant investigation.
Normal Range
- Normal Findings (Negative Result): Benign endometrial tissue with normal architecture, appropriate glandular-stromal ratio, proliferative or secretory phase changes consistent with cycle phase, absence of malignancy, hyperplasia, or significant inflammation.
- Normal vs. Abnormal Interpretation: NORMAL - Benign endometrial tissue appropriate to cycle phase; ABNORMAL - Endometrial hyperplasia, malignancy, atypical findings, chronic endometritis, or other significant pathology.
- Measurement Unit: Histopathological diagnosis; qualitative microscopic assessment; tissue grading and classification per standard pathology nomenclature.
- Reference Range: Not applicable as this is a tissue diagnosis test; results are descriptive rather than numerical.
Interpretation
- Benign Endometrial Tissue: Indicates normal endometrial histology; excludes malignancy and significant pathology; may explain symptoms through normal anatomy or functional causes.
- Endometrial Hyperplasia (Simple, Complex, or Atypical): Indicates abnormal proliferation of endometrial glands; atypical hyperplasia carries increased risk for malignant progression (up to 30%); requires close monitoring and potential intervention.
- Endometrial Malignancy (Carcinoma): Indicates presence of cancerous cells; requires staging, further imaging, and oncologic management; includes adenocarcinoma (most common), sarcoma, or other malignant histology.
- Chronic Endometritis: Indicates chronic inflammation within endometrial tissue; may be associated with infertility, recurrent miscarriage, or persistent abnormal bleeding; presence of plasma cells confirms diagnosis.
- Endometrial Polyps: Benign lesions that may cause abnormal bleeding; typically managed by removal; rarely malignant but require confirmation of benign nature.
- Factors Affecting Interpretation: Cycle phase at biopsy, hormonal therapy use, menstrual status (pre/post-menopausal), presence of intrauterine device (IUD), prior uterine procedures, specimen adequacy, and specific pathologist expertise.
- Clinical Significance of Patterns: Proliferative phase findings suggest ovulation; secretory phase findings confirm ovulation; anovulatory patterns may indicate hormonal dysfunction; uniform hyperplasia suggests unopposed estrogen exposure.
Associated Organs
- Primary Organ System: Female reproductive system; specifically the uterus (endometrium/uterine lining).
- Related Organ Systems: Ovaries (hormonal regulation), hypothalamic-pituitary axis (endocrine control), fallopian tubes (in cases of infection), and peritoneal cavity (metastatic spread risk in malignancy).
- Medical Conditions Associated with Abnormal Results: Endometrial adenocarcinoma, endometrial hyperplasia, chronic endometritis, polycystic ovary syndrome (PCOS), obesity-related endometrial changes, tamoxifen-induced endometrial pathology, unopposed estrogen exposure, endometrial polyps, and asherman syndrome.
- Diseases Diagnosed or Monitored: Endometrial cancer, endometrial hyperplasia with atypia, chronic endometritis, infertility secondary to endometrial pathology, recurrent pregnancy loss, abnormal uterine bleeding of unclear etiology, and postmenopausal bleeding disorders.
- Potential Complications with Abnormal Results: Metastatic cancer spread (if malignancy detected), progressive endometrial hyperplasia leading to cancer, sepsis or severe infection (if untreated endometritis), prolonged abnormal bleeding leading to anemia, infertility complications, and need for hysterectomy in advanced cases.
- Biopsy-Related Risks: Uterine perforation (rare), bleeding, infection, cramping, spotting, and minimal scarring; XL biopsy may carry slightly higher risk due to increased tissue sampling.
Follow-up Tests
- If Malignancy Detected: Comprehensive pelvic ultrasound, chest X-ray, CT abdomen/pelvis, MRI pelvis for staging, CA-125 tumor marker, endometrial cancer staging workup, possible hysterectomy with staging surgery, and oncology consultation.
- If Endometrial Hyperplasia Detected: Repeat endometrial biopsy in 3-6 months, progestin therapy initiation, reassessment ultrasound, hormone level evaluation, and possible hysterectomy if atypical hyperplasia present or unresponsive to treatment.
- If Chronic Endometritis Detected: Antibiotic therapy course, repeat biopsy post-treatment to confirm resolution (especially if infertility-related), hysterosalpingography if tubal factors suspected, and immunologic evaluation in recurrent cases.
- For Abnormal Uterine Bleeding: Pelvic ultrasound, hysteroscopy, coagulation studies, full blood count (hemoglobin/hematocrit for anemia), thyroid function tests, and possible imaging of polyps or fibroids.
- For Infertility Investigation: Semen analysis, ovulation studies, tubal patency assessment, hormone profiles (FSH, LH, progesterone), hysterosalpingography, and genetic counseling if recurrent pregnancy loss.
- Monitoring Frequency: Benign findings: no follow-up biopsy needed; hyperplasia: repeat biopsy at 3-6 months; malignancy: staging and treatment planning within 2-4 weeks; chronic endometritis: post-treatment confirmation within 4-8 weeks.
- Related Complementary Tests: Hysteroscopy with direct visualization, saline infusion sonography (SIS), 3D ultrasound, endometrial receptivity assay (ERA) for implantation studies, microbiome analysis for chronic endometritis, and immunohistochemistry for biomarker assessment.
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for uterine biopsy as this is a tissue sampling procedure, not a blood test.
- Pre-Procedure Instructions: Empty bladder before procedure for better visualization; may eat and drink normally before appointment; schedule during follicular phase when possible for optimal tissue sampling; avoid heavy exercise day of procedure.
- Medications to Avoid: Aspirin or NSAIDs (72 hours prior) to reduce bleeding risk; warfarin or other anticoagulants (coordinate with prescribing physician); heavy ibuprofen use; avoid blood-thinning supplements such as garlic, ginger, or omega-3 fish oil (1 week prior).
- Other Preparation Requirements: Confirm negative pregnancy status (urine or serum hCG if indicated); obtain informed consent after thorough explanation of procedure; arrange transportation if sedation used; wear comfortable, loose-fitting clothing; inform physician of allergies (latex, iodine, anesthetics); discontinue menstrual flow or obtain procedure during non-bleeding days if possible; arrange for pelvic rest and abstinence 48 hours post-procedure.
- Post-Procedure Care: May resume normal diet immediately; avoid tampons for 2 weeks; no sexual intercourse for 48 hours; expect light spotting or mild cramping for 24-48 hours; take acetaminophen as needed for discomfort; report heavy bleeding, fever, severe pain, or signs of infection to healthcare provider immediately.

How our test process works!